EMA Recommends Granting a Conditional Marketing Authorisation for Linvoseltamab By Ogkologos - April 10, 2025 364 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of patients with relapsed and refractory multiple myeloma Source RELATED ARTICLESMORE FROM AUTHOR Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma EMA Recommends Extension of Therapeutic Indications for Retifanlimab MOST POPULAR Efficacy of a Bispecific Monoclonal Antibody Glofitamab for Relapsed or Refractory... December 19, 2022 Genetic Testing for Bladder Cancer: What People With Cancer and Their... March 23, 2023 Embryos in the Womb Can Get Gene Mutations That Lead to... April 28, 2022 FDA Approves Updated Drug Labelling Including New Indications and Dosing Regimens... January 9, 2023 Load more HOT NEWS Teen Helps Mom With Cancer Shave Her Head, Then Turns To... FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory Marginal Zone Lymphoma ESMO Gynaecological Cancers Congress 2025, Vienna, Austria, 19-21 June Tackling under-representation of Black data scientists in cancer research
